Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 26

PMID 35216369

Authors

Adebayo J Molehin

Donald P McManus

Hong You

Affiliations

Soon will be listed here.

Abstract

Schistosomiasis, caused by human trematode blood flukes (schistosomes), remains one of the most prevalent and serious of the neglected tropical parasitic diseases. Currently, treatment of schistosomiasis relies solely on a single drug, the anthelmintic praziquantel, and with increased usage in mass drug administration control programs for the disease, the specter of drug resistance developing is a constant threat. Vaccination is recognized as one of the most sustainable options for the control of any pathogen, but despite the discovery and reporting of numerous potentially promising schistosome vaccine antigens, to date, no schistosomiasis vaccine for human or animal deployment is available. This is despite the fact that ranked such an intervention as one of the top 10 vaccines that need to be urgently developed to improve public health globally. This review summarizes current progress of schistosomiasis vaccines under clinical development and advocates the urgent need for the establishment of a revolutionary and effective anti-schistosome vaccine pipeline utilizing cutting-edge technologies (including developing mRNA vaccines and exploiting CRISPR-based technologies) to provide novel insight into future vaccine discovery, design, manufacture and deployment.

Citing Articles

Attitudes and acceptance of vaccination against neglected tropical diseases: A multi-country study in Asia.

Wong L, Lee H, Alias H, Seheli F, Lachyan A, Nguyen D Hum Vaccin Immunother. 2025; 21(1):2471702.

PMID: 40050267 PMC: 11901362. DOI: 10.1080/21645515.2025.2471702.

Evaluating the Immunoprotective and Diagnostic Potential of Schistosoma mansoni Epitopes from Sm050890 and Sm141290 Proteins Identified Through Reverse Vaccinology.

de Oliveira F, Lopes G, Ribeiro R, Villar J, Fonseca C, Lopes D Acta Parasitol. 2025; 70(1):14.

PMID: 39775981 DOI: 10.1007/s11686-024-00981-1.

Mathematical model of voluntary vaccination against schistosomiasis.

Lopez S, Majid S, Syed R, Rychtar J, Taylor D PeerJ. 2024; 12:e16869.

PMID: 39670094 PMC: 11636677. DOI: 10.7717/peerj.16869.

Vaccine value profile for schistosomiasis.

Yamey G, McDade K, Anderson R, Bartsch S, Bottazzi M, Diemert D Vaccine. 2024; :126020.

PMID: 39592316 PMC: 11754535. DOI: 10.1016/j.vaccine.2024.05.068.

Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities.

Alibrahim A, Elkholy W, El-Derbawy M, Zahran N, Alexiou A, Papadakis M Immun Inflamm Dis. 2024; 12(11):e70054.

PMID: 39560407 PMC: 11574878. DOI: 10.1002/iid3.70054.

References

Tchuente L, Rollinson D, Stothard J, Molyneux D . Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies. Infect Dis Poverty. 2017; 6(1):42. PMC: 5319063. DOI: 10.1186/s40249-017-0256-8. View

Molehin A, Sennoune S, Zhang W, Rojo J, Siddiqui A, Herrera K . Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. Parasitol Res. 2017; 116(11):3175-3188. PMC: 5660642. DOI: 10.1007/s00436-017-5634-4. View

Dadara A, Skelly P . Gene suppression in schistosomes using RNAi. Methods Mol Biol. 2014; 1201:143-64. DOI: 10.1007/978-1-4939-1438-8_8. View

McManus D, Bergquist R, Cai P, Ranasinghe S, Tebeje B, You H . Schistosomiasis-from immunopathology to vaccines. Semin Immunopathol. 2020; 42(3):355-371. PMC: 7223304. DOI: 10.1007/s00281-020-00789-x. View

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

Hagen J, Scheerlinck J, Gasser R . Knocking down schistosomes - promise for lentiviral transduction in parasites. Trends Parasitol. 2015; 31(7):324-32. DOI: 10.1016/j.pt.2015.03.009. View

Duthie M, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J . Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against . Front Immunol. 2018; 9:2420. PMC: 6199377. DOI: 10.3389/fimmu.2018.02420. View

Leger E, Webster J . Hybridizations within the Genus Schistosoma: implications for evolution, epidemiology and control. Parasitology. 2016; 144(1):65-80. DOI: 10.1017/S0031182016001190. View

Kariuki T, Farah I . Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model. Parasite Immunol. 2005; 27(7-8):281-8. DOI: 10.1111/j.1365-3024.2005.00783.x. View

10.

Keitel W, Potter G, Diemert D, Bethony J, El Sahly H, Kennedy J . A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019; 37(43):6500-6509. PMC: 6771426. DOI: 10.1016/j.vaccine.2019.08.075. View

11.

Hagen J, Scheerlinck J, Young N, Gasser R, Kalinna B . Prospects for Vector-Based Gene Silencing to Explore Immunobiological Features of Schistosoma mansoni. Adv Parasitol. 2015; 88:85-122. DOI: 10.1016/bs.apar.2015.02.002. View

12.

Karmakar S, Zhang W, Ahmad G, Torben W, Alam M, Le L . Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine. 2014; 32(11):1296-303. PMC: 3934627. DOI: 10.1016/j.vaccine.2013.12.057. View

13.

Dadara A, Li Y, Xiong T, Zhou J, Williams G, McManus D . DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine. 2008; 26(29-30):3617-25. PMC: 2567122. DOI: 10.1016/j.vaccine.2008.04.080. View

14.

Jang-Lee J, Curwen R, Ashton P, Tissot B, Mathieson W, Panico M . Glycomics analysis of Schistosoma mansoni egg and cercarial secretions. Mol Cell Proteomics. 2007; 6(9):1485-99. DOI: 10.1074/mcp.M700004-MCP200. View

15.

Gaze S, Driguez P, Pearson M, Mendes T, Doolan D, Trieu A . An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog. 2014; 10(3):e1004033. PMC: 3968167. DOI: 10.1371/journal.ppat.1004033. View

16.

Toor J, Alsallaq R, Truscott J, Turner H, Werkman M, Gurarie D . Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?. Clin Infect Dis. 2018; 66(suppl_4):S245-S252. PMC: 5982704. DOI: 10.1093/cid/ciy001. View

17.

Mo A, Colley D . Workshop report: Schistosomiasis vaccine clinical development and product characteristics. Vaccine. 2016; 34(8):995-1001. DOI: 10.1016/j.vaccine.2015.12.032. View

18.

Du X, McManus D, French J, Jones M, You H . CRISPR/Cas9: A new tool for the study and control of helminth parasites. Bioessays. 2020; 43(1):e2000185. DOI: 10.1002/bies.202000185. View

19.

Stylianou A, Hadjichrysanthou C, Truscott J, Anderson R . Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities. Parasit Vectors. 2017; 10(1):294. PMC: 5474049. DOI: 10.1186/s13071-017-2227-0. View

20.

. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature. 2009; 460(7253):345-51. PMC: 3747554. DOI: 10.1038/nature08140. View